Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 442

1.

Narrative review: Fabry disease.

Clarke JT.

Ann Intern Med. 2007 Mar 20;146(6):425-33. Review.

PMID:
17371887
2.

Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.

Schaefer RM, Tylki-Szymańska A, Hilz MJ.

Drugs. 2009 Nov 12;69(16):2179-205. doi: 10.2165/11318300-000000000-00000. Review.

PMID:
19852524
3.

Fabry disease: cardiac manifestations and therapeutic options.

Pierre-Louis B, Kumar A, Frishman WH.

Cardiol Rev. 2009 Jan-Feb;17(1):31-5. doi: 10.1097/CRD.0b013e31818adc50. Review.

PMID:
19092368
4.

Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters.

Koskenvuo JW, Hartiala JJ, Nuutila P, Kalliokoski R, Viikari JS, Engblom E, Penttinen M, Knuuti J, Mononen I, Kantola IM.

J Inherit Metab Dis. 2008 Jun;31(3):432-41. doi: 10.1007/s10545-008-0848-3. Epub 2008 May 23.

PMID:
18509742
5.

The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.

Morel CF, Clarke JT.

Expert Opin Biol Ther. 2009 May;9(5):631-9. doi: 10.1517/14712590902902296 . Review.

PMID:
19368525
6.

[Fabry disease. An interdisciplinary challenge].

Cybulla M, Neumann HP.

Dtsch Med Wochenschr. 2007 Oct;132(43):2271-7. Review. German.

PMID:
17940933
7.

Fabry disease: molecular genetics of the inherited nephropathy.

Desnick RJ, Astrin KH, Bishop DF.

Adv Nephrol Necker Hosp. 1989;18:113-27. Review.

PMID:
2564247
8.

Enzyme replacement therapy of Fabry disease.

Clarke JT, Iwanochko RM.

Mol Neurobiol. 2005 Aug;32(1):43-50. Review.

PMID:
16077182
9.

Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.

Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O'Callaghan M.

Kidney Int. 2002 Dec;62(6):1933-46.

PMID:
12427118
10.

Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).

Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R; FOS European Investigators.

J Med Genet. 2005 Mar;42(3):247-52.

11.

[Fabry disease--a provocation for pediatrics].

Hoffmann B, Mayatepek E.

Klin Padiatr. 2006 Jan-Feb;218(1):38-40. German.

PMID:
16432775
12.

Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.

Breunig F, Wanner C.

J Nephrol. 2008 Jan-Feb;21(1):32-7. Review.

PMID:
18264934
13.

Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.

Wang RY, Abe JT, Cohen AH, Wilcox WR.

J Inherit Metab Dis. 2008 Dec;31 Suppl 2:S369-74. doi: 10.1007/s10545-008-0930-x. Epub 2008 Oct 21.

PMID:
18937048
14.

[Neurological manifestations of Fabry disease].

Mendióroz M, Fernández-Cadenas I, Montaner J.

Rev Neurol. 2006 Dec 16-31;43(12):739-45. Review. Spanish.

15.

Clinical spectrum of Anderson Fabry disease in a Romanian family.

Tudor A, Muşat A, Doscan A, Bari M, Zapucioiu C, Urdea E, Cochior D, Peţa D.

Rom J Intern Med. 2006;44(2):201-10.

PMID:
17236300
16.
17.

[Fabry disease in Spain: first analysis of the response to enzyme replacement therapy].

Rivera Gallego A, López Rodríguez M, Barbado Hernández FJ, Barba Romero MA, García de Lorenzo Y Mateos A, Pintos Morelle G; Grupo Español de Estudio de Fabry Outcome Survey.

Med Clin (Barc). 2006 Oct 7;127(13):481-4. Spanish.

PMID:
17043001
18.

Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.

Ziegler RJ, Yew NS, Li C, Cherry M, Berthelette P, Romanczuk H, Ioannou YA, Zeidner KM, Desnick RJ, Cheng SH.

Hum Gene Ther. 1999 Jul 1;10(10):1667-82.

PMID:
10428212
19.

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.

Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M, Quirk JM, Zirzow GC, Borowski M, Loveday K, Anderson T, Gillespie F, Oliver KL, Jeffries NO, Doo E, Liang TJ, Kreps C, Gunter K, Frei K, Crutchfield K, Selden RF, Brady RO.

Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):365-70.

20.

Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.

Ortiz A, Oliveira JP, Wanner C, Brenner BM, Waldek S, Warnock DG.

Nat Clin Pract Nephrol. 2008 Jun;4(6):327-36. doi: 10.1038/ncpneph0806. Epub 2008 Apr 22.

PMID:
18431378
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk